121 related articles for article (PubMed ID: 28662185)
1. PD1 is highly expressed in diffuse large B-cell lymphoma with hepatitis B virus infection.
Liu Z; Li S; Liu Y; Guo W; Bai O
PLoS One; 2017; 12(6):e0180390. PubMed ID: 28662185
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis B virus-associated diffuse large B-cell lymphoma: unique clinical features, poor outcome, and hepatitis B surface antigen-driven origin.
Deng L; Song Y; Young KH; Hu S; Ding N; Song W; Li X; Shi Y; Huang H; Liu W; Zheng W; Wang X; Xie Y; Lin N; Tu M; Ping L; Ying Z; Zhang C; Sun Y; Zhu J
Oncotarget; 2015 Sep; 6(28):25061-73. PubMed ID: 26314957
[TBL] [Abstract][Full Text] [Related]
3. The impact of hepatitis B virus (HBV) infection on clinical outcomes of patients with diffuse large B-cell lymphoma.
Law MF; Lai HK; Chan HN; Ha CY; Ng C; Yeung YM; Yip SF
Eur J Cancer Care (Engl); 2015; 24(1):117-24. PubMed ID: 25848698
[TBL] [Abstract][Full Text] [Related]
4. Clinical and prognostic analysis of hepatitis B virus infection in diffuse large B-cell lymphoma.
Wang F; Xu RH; Luo HY; Zhang DS; Jiang WQ; Huang HQ; Sun XF; Xia ZJ; Guan ZZ
BMC Cancer; 2008 Apr; 8():115. PubMed ID: 18433487
[TBL] [Abstract][Full Text] [Related]
5. Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are HBsAg-negative/ HBcAb-positive: a multicenter retrospective study.
Ji D; Cao J; Hong X; Li J; Wang J; Chen F; Wang C; Zou S
Eur J Haematol; 2010 Sep; 85(3):243-50. PubMed ID: 20491883
[TBL] [Abstract][Full Text] [Related]
6. The association of the hepatitis B virus infection and diffuse large B-cell lymphoma.
Yu G; Han J; Xu J
Saudi Med J; 2024 May; 45(5):490-494. PubMed ID: 38734435
[TBL] [Abstract][Full Text] [Related]
7. PD1 and PDL1 expression in primary central nervous system diffuse large B-cell lymphoma are frequent and expression of PD1 predicts poor survival.
Four M; Cacheux V; Tempier A; Platero D; Fabbro M; Marin G; Leventoux N; Rigau V; Costes-Martineau V; Szablewski V
Hematol Oncol; 2017 Dec; 35(4):487-496. PubMed ID: 27966264
[TBL] [Abstract][Full Text] [Related]
8.
Liu Z; Li S; Guo W; Wang Y; Wang M; Bai O
Biomed Res Int; 2017; 2017():1967648. PubMed ID: 29209623
[TBL] [Abstract][Full Text] [Related]
9. Risk of HBV reactivation in relapsed or refractory diffuse large B-cell lymphoma patients receiving Bruton tyrosine kinase inhibitors therapy.
Ni Y; Gao L; Lu Y; Ye S; Zhou L; Qian W; Liang A; Li P
Front Immunol; 2022; 13():982346. PubMed ID: 36119029
[TBL] [Abstract][Full Text] [Related]
10. A retrospective analysis of primary gastric diffuse large B-cell lymphoma with or without concomitant mucosa-associated lymphoid tissue (MALT) lymphoma components.
Li X; Xia B; Guo S; Zhan Z; Zhang L; Zhao D; Wu X; Zhang Y
Ann Hematol; 2013 Jun; 92(6):807-15. PubMed ID: 23417758
[TBL] [Abstract][Full Text] [Related]
11. [Expression of dendritic cell marker CD21 is a positive prognostic factor in diffuse large B-cell lymphoma].
Yao WK; Wang YP; Peng F; Zheng Y; Zou YB; Gao JN; Liu XL
Zhonghua Bing Li Xue Za Zhi; 2012 Dec; 41(12):818-22. PubMed ID: 23324230
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Value of Anemia and C-Reactive Protein Levels in Diffuse Large B-Cell Lymphoma.
Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):671-9. PubMed ID: 26361646
[TBL] [Abstract][Full Text] [Related]
13. Clinical analysis and prognostic significance of hepatitis B virus infections for diffuse large B-cell lymphoma with or without rituximab therapy.
Xie W; Zhou D; Hu K; Xiao X; Huang W; He J; Shi J; Luo Y; Zhang J; Lin M; Cai Z; Huang H; Ye X
Exp Ther Med; 2013 Jul; 6(1):109-114. PubMed ID: 23935730
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological and prognostic features of hepatitis B virus-associated diffuse large B-cell lymphoma: a single-center retrospective study in China.
Chen DG; Chen G; Wang C; Ke LF; Wu H; He HM; Yang Y; Chen YP
Infect Agent Cancer; 2021 Aug; 16(1):57. PubMed ID: 34404436
[TBL] [Abstract][Full Text] [Related]
15. [Efficacy and prognostic analysis of relapsed/refractory diffuse large B-cell lymphoma patients with hepatitis B virus infection].
Fang Y; Wang L; Qian Y; Zhao WL
Zhonghua Xue Ye Xue Za Zhi; 2018 Dec; 39(12):1017-1020. PubMed ID: 30612404
[No Abstract] [Full Text] [Related]
16. [Analysis of survival and prognosis in 409 newly diagnosed patients with diffuse large B-cell lymphoma].
Wen J; Zhou J; Liu Z; Liu T; Xu C
Zhonghua Xue Ye Xue Za Zhi; 2014 Apr; 35(4):318-24. PubMed ID: 24759020
[TBL] [Abstract][Full Text] [Related]
17. [The clinical characteristics of 681 patients with diffuse large B-cell lymphoma].
Wen JJ; Liu ZB; Xu J; Xu CG
Zhonghua Xue Ye Xue Za Zhi; 2012 Dec; 33(12):1004-9. PubMed ID: 23363791
[TBL] [Abstract][Full Text] [Related]
18. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in China: a 10-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group.
Li X; Liu Z; Cao J; Hong X; Wang J; Chen F; Wang C; Zou S; Li J; Shen Z
Ann Hematol; 2012 Jun; 91(6):837-45. PubMed ID: 22160255
[TBL] [Abstract][Full Text] [Related]
19. Expression of BAFF-R, but not BAFF, is an independent prognostic factor in diffuse large B-cell lymphoma patients treated with R-CHOP.
Wang Y; Li YJ; Jiang WQ; Rao HL; Huang JJ; Xia Y; Bi X; Sun P; Huang HQ; Lin TY; Guan ZZ; Li ZM
Ann Hematol; 2015 Nov; 94(11):1865-73. PubMed ID: 26327569
[TBL] [Abstract][Full Text] [Related]
20. [Expression of PD-1, TIM-3, LAG-3 and BTLA in diffuse large B-cell lymphoma and its effect on prognosis].
Liu XY; Yuan XL; Ma RJ; Xu H; Yang SW; Nie L; Zhang L; Hu AX; Li Z; Zhu ZM
Zhonghua Yi Xue Za Zhi; 2020 Sep; 100(36):2846-2853. PubMed ID: 32988145
[No Abstract] [Full Text] [Related]
[Next] [New Search]